MET and non-small cell lung carcinoma: This review specifically focuses on capmatinib (INC280), which received U.S. Food and Drug Administration (FDA) approval for MET exon 14 skip mutations in metastatic NSCLC on 10 August 2022 and by the European Medicines Agency (EMA) on 20 June 2022 specifically for those patients who have received immunotherapy or platinum-based chemotherapy or both [37,38].